Travere Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
During the fiscal quarter ended December 31, 2025, certain of our directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, as set forth below. Each 10b5-1 plan listed below is part of such individual’s long-term asset diversification, tax and/or financial planning strategy, and has been entered into in accordance with the terms of our Insider Trading Policy. Under the terms of the plans, once the plans are in effect, the individuals listed below have no discretion or control over the timing or effectuation of any transactions in our securities pursuant to the plans, and sales will be made only if the stock meets the minimum price thresholds and/or other requirements specified in the applicable plan. Some of the planned sales relate to shares required to be sold by such individual to cover the tax withholding obligation in connection with the settlement of vested restricted stock units and/or performance restricted stock units. Each such director and/or officer continues to be subject to our stock ownership guidelines, and the execution of all potential sales under the plan would not by themselves cause any such individual to be out of compliance with the requirements of our stock ownership guidelines.
Trading Arrangements Adopted:
| Name & Title | Date Adopted | Character of Trading Arrangement (1) | Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement | Expiration Date (2) |
|---|---|---|---|---|
| Roy Baynes,member of our Board of Directors | November 17, 2025 | Rule 10b5-1 Trading Arrangement | Up to 61,500 shares (3) | November 13, 2026 |
| Timothy Coughlin,member of our Board of Directors | November 19, 2025 | Rule 10b5-1 Trading Arrangement | Up to 13,250 shares (3) | February 25, 2027 |
| Gary Lyons,chair of our Board of Directors | November 11, 2025 | Rule 10b5-1 Trading Arrangement | Up to 8,000 shares (4) | May 17, 2026 |
| Jeffrey Meckler,member of our Board of Directors | November 17, 2025 | Rule 10b5-1 Trading Arrangement | Up to 8,000 shares (4) | May 18, 2026 |
| 1 | Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act (the “Rule”). |
| 2 | Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales and (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule. |
| 3 | Includes shares underlying stock options expiring in May 2028. |
| 4 | Consists of shares of underlying stock options expiring in May 2026. |
Trading Arrangements Terminated:
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.